Genitourinary Syndrome of Menopause (GSM) Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology 

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Genitourinary Syndrome of Menopause (GSM) Market 

5.1. COVID-19 Landscape: Genitourinary Syndrome of Menopause (GSM) Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Genitourinary Syndrome of Menopause (GSM) Market, By Treatment Type

8.1. Genitourinary Syndrome of Menopause (GSM) Market, by Treatment Type

8.1.1. Vaginal estrogen therapies

8.1.1.1. Market Revenue and Forecast

8.1.2. Oral SERM therapies

8.1.2.1. Market Revenue and Forecast

8.1.3. Vaginal DHEA therapies

8.1.3.1. Market Revenue and Forecast

8.1.4. Non-hormonal moisturisers and lubricants

8.1.4.1. Market Revenue and Forecast

8.1.5. Energy-based devices and procedures

8.1.5.1. Market Revenue and Forecast

Chapter 9. Global Genitourinary Syndrome of Menopause (GSM) Market, By Delivery Modality

9.1. Genitourinary Syndrome of Menopause (GSM) Market, by Delivery Modality

9.1.1. Prescription therapies

9.1.1.1. Market Revenue and Forecast

9.1.2. OTC therapies

9.1.2.1. Market Revenue and Forecast

9.1.3. Device-based procedures

9.1.3.1. Market Revenue and Forecast

Chapter 10. Global Genitourinary Syndrome of Menopause (GSM) Market, By Indication Focus

10.1. Genitourinary Syndrome of Menopause (GSM) Market, by Indication Focus

10.1.1. Vaginal dryness and irritation

10.1.1.1. Market Revenue and Forecast

10.1.2. Dyspareunia

10.1.2.1. Market Revenue and Forecast

10.1.3. Urinary symptoms

10.1.3.1. Market Revenue and Forecast

10.1.4. Mixed GSM symptom management

10.1.4.1. Market Revenue and Forecast

Chapter 11. Global Genitourinary Syndrome of Menopause (GSM) Market, By Distribution Channel

11.1. Genitourinary Syndrome of Menopause (GSM) Market, by Distribution Channel

11.1.1. Retail pharmacy

11.1.1.1. Market Revenue and Forecast

11.1.2. Hospital pharmacy

11.1.2.1. Market Revenue and Forecast

11.1.3. Online pharmacy and e-commerce

11.1.3.1. Market Revenue and Forecast

11.1.4. Specialty pharmacy

11.1.4.1. Market Revenue and Forecast

Chapter 12. Global Genitourinary Syndrome of Menopause (GSM) Market, By End User

12.1. Genitourinary Syndrome of Menopause (GSM) Market, by End User

12.1.1. Hospitals

12.1.1.1. Market Revenue and Forecast

12.1.2. Gynaecology and women’s health clinics

12.1.2.1. Market Revenue and Forecast

12.1.3. Ambulatory surgical centres

12.1.3.1. Market Revenue and Forecast

12.1.4. Home care and self-care

12.1.4.1. Market Revenue and Forecast

Chapter 13. Global Genitourinary Syndrome of Menopause (GSM) Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Treatment Type

13.1.2. Market Revenue and Forecast, by Delivery Modality

13.1.3. Market Revenue and Forecast, by Indication Focus

13.1.4. Market Revenue and Forecast, by Distribution Channel

13.1.5. Market Revenue and Forecast, by End User

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Treatment Type

13.1.6.2. Market Revenue and Forecast, by Delivery Modality

13.1.6.3. Market Revenue and Forecast, by Indication Focus

13.1.6.4. Market Revenue and Forecast, by Distribution Channel

13.1.6.5. Market Revenue and Forecast, by End User  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Treatment Type

13.1.7.2. Market Revenue and Forecast, by Delivery Modality

13.1.7.3. Market Revenue and Forecast, by Indication Focus

13.1.7.4. Market Revenue and Forecast, by Distribution Channel

13.1.7.5. Market Revenue and Forecast, by End User

13.2. Europe

13.2.1. Market Revenue and Forecast, by Treatment Type

13.2.2. Market Revenue and Forecast, by Delivery Modality

13.2.3. Market Revenue and Forecast, by Indication Focus

13.2.4. Market Revenue and Forecast, by Distribution Channel  

13.2.5. Market Revenue and Forecast, by End User  

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Treatment Type

13.2.6.2. Market Revenue and Forecast, by Delivery Modality

13.2.6.3. Market Revenue and Forecast, by Indication Focus

13.2.7. Market Revenue and Forecast, by Distribution Channel  

13.2.8. Market Revenue and Forecast, by End User  

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Treatment Type

13.2.9.2. Market Revenue and Forecast, by Delivery Modality

13.2.9.3. Market Revenue and Forecast, by Indication Focus

13.2.10. Market Revenue and Forecast, by Distribution Channel

13.2.11. Market Revenue and Forecast, by End User

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Treatment Type

13.2.12.2. Market Revenue and Forecast, by Delivery Modality

13.2.12.3. Market Revenue and Forecast, by Indication Focus

13.2.12.4. Market Revenue and Forecast, by Distribution Channel

13.2.13. Market Revenue and Forecast, by End User

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Treatment Type

13.2.14.2. Market Revenue and Forecast, by Delivery Modality

13.2.14.3. Market Revenue and Forecast, by Indication Focus

13.2.14.4. Market Revenue and Forecast, by Distribution Channel

13.2.15. Market Revenue and Forecast, by End User

13.3. APAC

13.3.1. Market Revenue and Forecast, by Treatment Type

13.3.2. Market Revenue and Forecast, by Delivery Modality

13.3.3. Market Revenue and Forecast, by Indication Focus

13.3.4. Market Revenue and Forecast, by Distribution Channel

13.3.5. Market Revenue and Forecast, by End User

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Treatment Type

13.3.6.2. Market Revenue and Forecast, by Delivery Modality

13.3.6.3. Market Revenue and Forecast, by Indication Focus

13.3.6.4. Market Revenue and Forecast, by Distribution Channel

13.3.7. Market Revenue and Forecast, by End User

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Treatment Type

13.3.8.2. Market Revenue and Forecast, by Delivery Modality

13.3.8.3. Market Revenue and Forecast, by Indication Focus

13.3.8.4. Market Revenue and Forecast, by Distribution Channel

13.3.9. Market Revenue and Forecast, by End User

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Treatment Type

13.3.10.2. Market Revenue and Forecast, by Delivery Modality

13.3.10.3. Market Revenue and Forecast, by Indication Focus

13.3.10.4. Market Revenue and Forecast, by Distribution Channel

13.3.10.5. Market Revenue and Forecast, by End User

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Treatment Type

13.3.11.2. Market Revenue and Forecast, by Delivery Modality

13.3.11.3. Market Revenue and Forecast, by Indication Focus

13.3.11.4. Market Revenue and Forecast, by Distribution Channel

13.3.11.5. Market Revenue and Forecast, by End User

13.4. MEA

13.4.1. Market Revenue and Forecast, by Treatment Type

13.4.2. Market Revenue and Forecast, by Delivery Modality

13.4.3. Market Revenue and Forecast, by Indication Focus

13.4.4. Market Revenue and Forecast, by Distribution Channel

13.4.5. Market Revenue and Forecast, by End User

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Treatment Type

13.4.6.2. Market Revenue and Forecast, by Delivery Modality

13.4.6.3. Market Revenue and Forecast, by Indication Focus

13.4.6.4. Market Revenue and Forecast, by Distribution Channel

13.4.7. Market Revenue and Forecast, by End User

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Treatment Type

13.4.8.2. Market Revenue and Forecast, by Delivery Modality

13.4.8.3. Market Revenue and Forecast, by Indication Focus

13.4.8.4. Market Revenue and Forecast, by Distribution Channel

13.4.9. Market Revenue and Forecast, by End User

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Treatment Type

13.4.10.2. Market Revenue and Forecast, by Delivery Modality

13.4.10.3. Market Revenue and Forecast, by Indication Focus

13.4.10.4. Market Revenue and Forecast, by Distribution Channel

13.4.10.5. Market Revenue and Forecast, by End User

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Treatment Type

13.4.11.2. Market Revenue and Forecast, by Delivery Modality

13.4.11.3. Market Revenue and Forecast, by Indication Focus

13.4.11.4. Market Revenue and Forecast, by Distribution Channel

13.4.11.5. Market Revenue and Forecast, by End User

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Treatment Type

13.5.2. Market Revenue and Forecast, by Delivery Modality

13.5.3. Market Revenue and Forecast, by Indication Focus

13.5.4. Market Revenue and Forecast, by Distribution Channel

13.5.5. Market Revenue and Forecast, by End User

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Treatment Type

13.5.6.2. Market Revenue and Forecast, by Delivery Modality

13.5.6.3. Market Revenue and Forecast, by Indication Focus

13.5.6.4. Market Revenue and Forecast, by Distribution Channel

13.5.7. Market Revenue and Forecast, by End User

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Treatment Type

13.5.8.2. Market Revenue and Forecast, by Delivery Modality

13.5.8.3. Market Revenue and Forecast, by Indication Focus

13.5.8.4. Market Revenue and Forecast, by Distribution Channel

13.5.8.5. Market Revenue and Forecast, by End User

Chapter 14. Company Profiles

14.1. Pfizer

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. AbbVie 

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Shionogi 

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Novo Nordisk 

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Mayne Pharma 

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Teva Pharmaceutical Industries 

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. DEKA 

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Church and Dwight 

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Reckitt

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Haleon 

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms